Second Generation Cell and Gene-Based Therapies 2020
DOI: 10.1016/b978-0-12-812034-7.00006-6
|View full text |Cite
|
Sign up to set email alerts
|

Pluripotent Stem Cell–Derived Islet Replacement Therapy for Diabetes

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2020
2020
2020
2020

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 68 publications
0
1
0
Order By: Relevance
“…Present methods, however, generate patient iPSC-derived β (SC-β) cells with low in vitro and in vivo function (Maxwell et al, 2020). In several ways, cell replacement therapy for type 1 diabetes (T1D) is a perfect first drug model to follow in the emerging field of regenerative medicine (Brandon et al, 2020).…”
Section: Introductionmentioning
confidence: 99%
“…Present methods, however, generate patient iPSC-derived β (SC-β) cells with low in vitro and in vivo function (Maxwell et al, 2020). In several ways, cell replacement therapy for type 1 diabetes (T1D) is a perfect first drug model to follow in the emerging field of regenerative medicine (Brandon et al, 2020).…”
Section: Introductionmentioning
confidence: 99%